TransCode Therapeutics, Inc. (RNAZ) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Market Cap | 4.71M |
| Enterprise Value | -13.1M |
| P/E Ratio | -0.13 |
| PEG Ratio | -0 |
| Price/Sales Ratio | 0 |
| Price/Book Ratio | 0.04 |
| Enterprise/Revenue | 0 |
| Enterprise/EBITDA | 0.25 |
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | March 31, 2026 |
| Profit Margin | 0 |
| Operating Margin | 0 |
| Return On Assets | -0.26 |
| Return On Equity | -0.99 |
| Revenue | 0 |
| Revenue/Share | 0 |
| Gross Profit | 0 |
| EBITDA | -34.31M |
| Net Income | -34.66M |
| Diluted EPS | -52.59 |
| Total Cash | 12.84M |
| Total Cash/Share | 14 |
| Total Debt | 0 |
| Total Debt/Equity | 0 |
| Current Ratio | 3.11 |
| Book Value Per Share | 157.61 |
| 52-Week Change | -26.32 |
| 52-Week High | 20.99 |
| 52-Week Low | 3.82 |
| Moving Average 50 Days | 7.28 |
| Moving Average 200 Days | 9.29 |
| Average Volume | 50,593 |
| Shares Outstanding | 950,301 |
| % Held by Institutions | 3.37 |
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | -42.75 |
| Last Split Factor | 1:28 |
| Last Split Date | May 15, 2025 |